AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34718884 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban or apixaban
Number of subjects: 1080
Study 34719115 — intervention group
Group type: EXPERIMENTAL
Intervention: Remdesivir
Number of subjects: 0
Study 34719198 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated intrathecal injections of autologous mesenchymal stem cells, dosage and duration not available
Number of subjects: 0
Study 34719715 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheal pepsin A measurement
Number of subjects: 297
Study 34719715 — intervention group
Group type: COMPARATOR
Intervention: Control group (no tracheal pepsin A measurement)
Number of subjects: 297
Study 34721255 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 Min Electrostimulation with the EXOPULSE Mollii Suit
Number of subjects: 0
Study 34721403 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab treatment
Number of subjects: 68
Study 34721420 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-CD25 induction
Number of subjects: 117
Study 34721420 — intervention group
Group type: COMPARATOR
Intervention: TCMR
Number of subjects: 117
Study 34722242 — intervention group
Group type: EXPERIMENTAL
Intervention: AGIG chemo-immunotherapy regimen (nab-paclitaxel + gemcitabine + IL-2 + GM-CSF)
Number of subjects: 64
Study 34722269 — intervention group
Group type: EXPERIMENTAL
Intervention: Regionally administered melphalan
Number of subjects: 2
Study 34722275 — intervention group
Group type: EXPERIMENTAL
Intervention: Upfront RT
Number of subjects: 198
Study 34722275 — intervention group
Group type: COMPARATOR
Intervention: Deferred RT
Number of subjects: 198
Study 34722563 — intervention group
Group type: EXPERIMENTAL
Intervention: MMGA (multimodal general anesthesia) using intravenous remifentanil, ketamine, dexmedetomidine, magnesium, and bupivacaine as a pecto-intercostal fascial block.
Number of subjects: 20
Study 34722563 — intervention group
Group type: EXPERIMENTAL
Intervention: MMGA (multimodal general anesthesia)
Number of subjects: 20
Study 34722661 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-inflammatory medications, specific type and dosage not available
Number of subjects: 0
Study 34722661 — intervention group
Group type: COMPARATOR
Intervention: Control group, specific treatment not available
Number of subjects: 0
Study 34722667 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiography-Derived IMR
Number of subjects: 0
Study 34722667 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34722810 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately hypofractionated intensity-modulated proton therapy (IMPT) targeting the prostate/seminal vesicles and pelvic lymph nodes, 6750 cGyRBE for prostate and 4500 cGyRBE for pelvic lymph nodes in 25 daily fractions, all received androgen-deprivation therapy.
Number of subjects: 56
Study 34722810 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of baseline GU symptoms
Number of subjects: 56
Study 34723054 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 1262
Study 34723634 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 0
Study 34723634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34723820 — intervention group
Group type: EXPERIMENTAL
Intervention: DOZE app (self-management intervention)
Number of subjects: 83
Study 34723822 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy (iCBT)
Number of subjects: 69
Study 34723822 — intervention group
Group type: EXPERIMENTAL
Intervention: Public-facing campaign addressing mental health stigma
Number of subjects: 69
Study 34723822 — intervention group
Group type: EXPERIMENTAL
Intervention: Service-level adjustments for staff
Number of subjects: 69
Study 34723822 — intervention group
Group type: EXPERIMENTAL
Intervention: Establishment of a suitable clinical training curriculum for health care professionals
Number of subjects: 69
Study 34723826 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace-based HIV self-testing using OraQuick test kits
Number of subjects: 0
Study 34723826 — intervention group
Group type: COMPARATOR
Intervention: Routine HTS at work premises
Number of subjects: 0
Study 34723824 — intervention group
Group type: EXPERIMENTAL
Intervention: FITxOlder (Community Health Worker-led Chinese Qigong mind-body exercise program)
Number of subjects: 49
Study 34723824 — intervention group
Group type: EXPERIMENTAL
Intervention: FITxOlder
Number of subjects: 49
Study 34723858 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine
Number of subjects: 0
Study 34724112 — intervention group
Group type: EXPERIMENTAL
Intervention: Optogenetic treatment (irreversible gene therapy) with specially designed goggles for light delivery
Number of subjects: 0
Study 34724115 — intervention group
Group type: EXPERIMENTAL
Intervention: 4SCAR-GD2 T-cell treatment
Number of subjects: 10
Study 34724226 — intervention group
Group type: EXPERIMENTAL
Intervention: Molibresib 75 mg once daily
Number of subjects: 0
Study 34724240 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous arginine therapy
Number of subjects: 0
Study 34724240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34724453 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily step counts measured using armband accelerometers worn for 7 days, with a median of 1170 steps daily.
Number of subjects: 531
Study 34724453 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily step counts measured using armband accelerometers worn for 7 days.
Number of subjects: 531
Study 34724566 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppressive therapy
Number of subjects: 544
Study 34724566 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss of HLA-B*40:02
Number of subjects: 544
Study 34724566 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-B*07:02 and HLA-B*40:01 genotypes and their loss
Number of subjects: 544
Study 34724624 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory confirmed dengue (LCD)
Number of subjects: 2004
Study 34724624 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-LCD
Number of subjects: 2004
Study 34724906 — intervention group
Group type: EXPERIMENTAL
Intervention: Responses from participants regarding their HDP experience
Number of subjects: 3202
Study 34725072 — intervention group
Group type: EXPERIMENTAL
Intervention: IV DEXA (24 mg)
Number of subjects: 60
Study 34725072 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 60
Study 34725077 — intervention group
Group type: EXPERIMENTAL
Intervention: In-bed leg cycling for 30 minutes daily for 14 consecutive days, initiated within 48 hours of spinal surgery.
Number of subjects: 45
Study 34725077 — intervention group
Group type: COMPARATOR
Intervention: In-bed leg cycling
Number of subjects: 45
Study 34725108 — intervention group
Group type: EXPERIMENTAL
Intervention: mTOR inhibitors (mTORis)
Number of subjects: 0
Study 34725108 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolic acid (MPA)
Number of subjects: 0
Study 34725214 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative short-course radiotherapy (SCRT) followed by CAPOX (capecitabine and oxaliplatin) and camrelizumab
Number of subjects: 30
Study 34725215 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34725289 — intervention group
Group type: EXPERIMENTAL
Intervention: Tregocel® nutraceutical supplement
Number of subjects: 107
Study 34725726 — intervention group
Group type: EXPERIMENTAL
Intervention: Needles with prostate cancer (PCa)
Number of subjects: 5
Study 34725726 — intervention group
Group type: COMPARATOR
Intervention: Needles without prostate cancer (PCa)
Number of subjects: 5
Study 34726532 — intervention group
Group type: EXPERIMENTAL
Intervention: Symmetric collateral pattern at CT angiography (CTA)
Number of subjects: 31
Study 34726532 — intervention group
Group type: EXPERIMENTAL
Intervention: Malignant collateral pattern at CT angiography (CTA)
Number of subjects: 31
Study 34726532 — intervention group
Group type: EXPERIMENTAL
Intervention: Other collateral pattern at CT angiography (CTA)
Number of subjects: 31
Study 34726579 — intervention group
Group type: EXPERIMENTAL
Intervention: PROMIS® short forms
Number of subjects: 884
Study 34726607 — intervention group
Group type: EXPERIMENTAL
Intervention: Participant-centric digital health study approach with high friction app-based assessments and wearable sensors.
Number of subjects: 365
Study 34726607 — intervention group
Group type: EXPERIMENTAL
Intervention: Participant engagement strategy with regular phone check-ins.
Number of subjects: 365
Study 34726610 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-delivered eHealth intervention (3 sessions delivered weekly over 3 weeks)
Number of subjects: 620
Study 34726610 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 620
Study 34726763 — intervention group
Group type: EXPERIMENTAL
Intervention: SQoL-6D Total score change
Number of subjects: 104
Study 34726763 — intervention group
Group type: EXPERIMENTAL
Intervention: Global Assessment of Benefit scale
Number of subjects: 104
Study 34726763 — intervention group
Group type: EXPERIMENTAL
Intervention: GASeous tool
Number of subjects: 104
Study 34726887 — intervention group
Group type: EXPERIMENTAL
Intervention: SY-5609, a selective, noncovalent inhibitor of CDK7
Number of subjects: 0
Study 34726887 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 34727366 — intervention group
Group type: EXPERIMENTAL
Intervention: HS-10234 25 mg daily for 7 days (D1-D7) followed by emtricitabine 200 mg QD for 7 days (D8-D14)
Number of subjects: 36
Study 34727366 — intervention group
Group type: COMPARATOR
Intervention: Emtricitabine 200 mg QD for 7 days (D1-D7) followed by HS-10234 25 mg QD for 7 days (D8-D14)
Number of subjects: 36
Study 34727741 — intervention group
Group type: EXPERIMENTAL
Intervention: Bridging therapy
Number of subjects: 1872
Study 34727741 — intervention group
Group type: COMPARATOR
Intervention: Mechanical thrombectomy (MT) alone
Number of subjects: 1872
Study 34727741 — intervention group
Group type: COMPARATOR
Intervention: Intravenous thrombolysis alone
Number of subjects: 1872
Study 34727875 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel (Abraxane, 125 mg/m2, D1, D8, D15 every 28 days)
Number of subjects: 80
Study 34727956 — intervention group
Group type: EXPERIMENTAL
Intervention: MedReviewRx software used for medication reviews
Number of subjects: 1000
Study 34727956 — intervention group
Group type: COMPARATOR
Intervention: Control group (before intervention)
Number of subjects: 1000
Study 34727972 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based salivary sampling protocol
Number of subjects: 19
Study 34727975 — intervention group
Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet
Number of subjects: 94
Study 34727975 — intervention group
Group type: COMPARATOR
Intervention: Low fat diet
Number of subjects: 94
Study 34728052 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular advancement device therapy
Number of subjects: 63
Study 34728052 — intervention group
Group type: COMPARATOR
Intervention: Control (not explicitly mentioned)
Number of subjects: 63
Study 34728392 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood gas analysis (bicarbonate, partial pressure of oxygen, and partial pressure of carbon dioxide)
Number of subjects: 62
Study 34728392 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood gas analysis
Number of subjects: 62
Study 34728392 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular collateralization assessment
Number of subjects: 62
Study 34728440 — intervention group
Group type: EXPERIMENTAL
Intervention: Message-based care only for 6 weeks
Number of subjects: 1000
Study 34728440 — intervention group
Group type: COMPARATOR
Intervention: Videoconference-psychotherapy only for 6 weeks
Number of subjects: 1000
Study 34728440 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly videoconference-psychotherapy
Number of subjects: 1000
Study 34728440 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly videoconference-psychotherapy plus message-based care
Number of subjects: 1000
Study 34728446 — intervention group
Group type: EXPERIMENTAL
Intervention: MyPal digital health platform (n=150)
Number of subjects: 300
Study 34728446 — intervention group
Group type: COMPARATOR
Intervention: Standard care (n=150)
Number of subjects: 300
Study 34728455 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning techniques including convolutional neural network, recurrent neural network, and Transformer applied to primary care data for predicting new-onset AF.
Number of subjects: 0
Study 34728530 — intervention group
Group type: EXPERIMENTAL
Intervention: Confirmed Diabetic Peripheral Neuropathy (DPN) in men at EDIC year 13/14
Number of subjects: 1006
Study 34728530 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal Michigan Neuropathy Screening Instrument (MNSI) examination or questionnaire scores in men
Number of subjects: 1006
Study 34728530 — intervention group
Group type: COMPARATOR
Intervention: Women with FSD and LUTS/UI
Number of subjects: 1006
Study 34728783 — intervention group
Group type: EXPERIMENTAL
Intervention: Athletes with SCI
Number of subjects: 145
Study 34728783 — intervention group
Group type: COMPARATOR
Intervention: Able-bodied controls
Number of subjects: 145
Study 34728783 — intervention group
Group type: COMPARATOR
Intervention: Non-athletes with SCI
Number of subjects: 145
Study 34728783 — intervention group
Group type: EXPERIMENTAL
Intervention: Athletes with SCI and able-bodied controls
Number of subjects: 145
Study 34729148 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal Medical Therapy (OMT)
Number of subjects: 765
Study 34729148 — intervention group
Group type: COMPARATOR
Intervention: Non-Optimal Medical Therapy (non-OMT)
Number of subjects: 765
Study 34729526 — intervention group
Group type: EXPERIMENTAL
Intervention: ATTRwt amyloidosis diagnoses in the United States
Number of subjects: 1069
Study 34729526 — intervention group
Group type: EXPERIMENTAL
Intervention: ATTRwt amyloidosis diagnoses by tissue biopsy
Number of subjects: 1069
Study 34729526 — intervention group
Group type: EXPERIMENTAL
Intervention: ATTRwt amyloidosis diagnoses by bone scintigraphy
Number of subjects: 1069
Study 34729526 — intervention group
Group type: EXPERIMENTAL
Intervention: ATTRv amyloidosis with cardiac mutation diagnoses
Number of subjects: 1069
Study 34729526 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportion of patients with ATTRwt amyloidosis diagnosed with NYHA functional class III/IV heart failure
Number of subjects: 1069
Study 34729628 — intervention group
Group type: EXPERIMENTAL
Intervention: knottin PET/CT
Number of subjects: 15
Study 34729682 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin (0.6 mg)
Number of subjects: 0
Study 34729767 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfibrinolysis defined as enzymatic fibrinolysis index (ROTEM EXTEM ML minus ROTEM APTEM ML) above 15%
Number of subjects: 390
Study 34729767 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzymatic fibrinolysis index > 15%
Number of subjects: 390
Study 34730004 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly diagnosed infections during hospitalization
Number of subjects: 2399
Study 34730004 — intervention group
Group type: COMPARATOR
Intervention: No newly diagnosed infections during hospitalization
Number of subjects: 2399
Study 34730535 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-enhanced behavioral activation treatment (Life Enhancement Treatment for Substance Use)
Number of subjects: 56
Study 34730541 — intervention group
Group type: EXPERIMENTAL
Intervention: Online therapy
Number of subjects: 6023
Study 34730541 — intervention group
Group type: COMPARATOR
Intervention: Face-to-Face therapy (F2F)
Number of subjects: 6023
Study 34730541 — intervention group
Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 6023
Study 34731011 — intervention group
Group type: EXPERIMENTAL
Intervention: OSATURBS Assessment Tool
Number of subjects: 0
Study 34731011 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 34731867 — intervention group
Group type: EXPERIMENTAL
Intervention: MIMS procedure (ab interno, stent-less, subconjunctival filtration)
Number of subjects: 31
Study 34731867 — intervention group
Group type: EXPERIMENTAL
Intervention: MIMS procedure (with iris clogging complication)
Number of subjects: 31
Study 34731884 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplant (auto-SCT) for ELN2017-FR patients
Number of subjects: 500
Study 34731884 — intervention group
Group type: COMPARATOR
Intervention: Allogeneic stem cell transplant (allo-SCT) for ELN2017-FR patients
Number of subjects: 500
Study 34731884 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplant (auto-SCT) for ELN2017-IR patients
Number of subjects: 500
Study 34731884 — intervention group
Group type: COMPARATOR
Intervention: Allogeneic stem cell transplant (allo-SCT) for ELN2017-IR patients
Number of subjects: 500
Study 34731884 — intervention group
Group type: EXPERIMENTAL
Intervention: ELN2017-FR group
Number of subjects: 500
Study 34731884 — intervention group
Group type: EXPERIMENTAL
Intervention: ELN2017-IR group
Number of subjects: 500
Study 34731884 — intervention group
Group type: EXPERIMENTAL
Intervention: ELN2017-not classifiable group
Number of subjects: 500
Study 34731884 — intervention group
Group type: EXPERIMENTAL
Intervention: ELN2017-AR group
Number of subjects: 500
Study 34732137 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypotaurine supplementation (H+)
Number of subjects: 33
Study 34732137 — intervention group
Group type: COMPARATOR
Intervention: Control (H-)
Number of subjects: 33
Study 34732178 — intervention group
Group type: EXPERIMENTAL
Intervention: TEACHH intervention
Number of subjects: 78
Study 34732233 — intervention group
Group type: EXPERIMENTAL
Intervention: Group SS - ONS in addition to normal diet up to 14 days preoperatively and postoperatively up to discharge
Number of subjects: 3
Study 34732233 — intervention group
Group type: EXPERIMENTAL
Intervention: Group SS-E - ONS in addition to normal diet up to 14 days preoperatively, postoperatively up to discharge and for an extended 90 days after discharge
Number of subjects: 3
Study 34732233 — intervention group
Group type: EXPERIMENTAL
Intervention: Group DS - ONS in addition to normal diet postoperatively up to discharge
Number of subjects: 3
Study 34732233 — intervention group
Group type: EXPERIMENTAL
Intervention: Group SS, Group SS-E, Group DS - ONS
Number of subjects: 3
Study 34732246 — intervention group
Group type: EXPERIMENTAL
Intervention: FABIANA-checklist (25-item version)
Number of subjects: 75
Study 34732246 — intervention group
Group type: EXPERIMENTAL
Intervention: FABIANA-checklist
Number of subjects: 75
Study 34732425 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-smokers
Number of subjects: 2439
Study 34732425 — intervention group
Group type: COMPARATOR
Intervention: Smokers
Number of subjects: 2439
Study 34732475 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to grocery store
Number of subjects: 9218
Study 34732475 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to public transport stop
Number of subjects: 9218
Study 34732475 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to children's playground
Number of subjects: 9218
Study 34732475 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to metropolitan parks
Number of subjects: 9218
Study 34732475 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximity to sport facilities or children's playground areas
Number of subjects: 9218
Study 34732475 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of adequate design for walking or cycling
Number of subjects: 9218
Study 34732475 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of living in a safe neighbourhood
Number of subjects: 9218
Study 34732478 — intervention group
Group type: EXPERIMENTAL
Intervention: Nudge alert addressing patient harm
Number of subjects: 0
Study 34732478 — intervention group
Group type: EXPERIMENTAL
Intervention: Nudge alert addressing increased out-of-pocket costs
Number of subjects: 0
Study 34732478 — intervention group
Group type: EXPERIMENTAL
Intervention: Nudge alert addressing psychological harm
Number of subjects: 0
Study 34732478 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study 34732478 — intervention group
Group type: EXPERIMENTAL
Intervention: Nudge alerts (all types)
Number of subjects: 0
Study 34732483 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace exercise intervention (2 hours of exercise per week for 12 weeks)
Number of subjects: 150
Study 34732483 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention group (2 hours of exercise per week for 4 weeks after the initial intervention)
Number of subjects: 150
Study 34732483 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace exercise intervention
Number of subjects: 150
Study 34732486 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted partial nephrectomy (RAPN)
Number of subjects: 50
Study 34732486 — intervention group
Group type: COMPARATOR
Intervention: Open partial nephrectomy (OPN)
Number of subjects: 50
Study 34732500 — intervention group
Group type: EXPERIMENTAL
Intervention: Lengthened dosing interval (from 8 to 12 weeks for infliximab users and from 2 to 3 weeks for adalimumab users)
Number of subjects: 148
Study 34732500 — intervention group
Group type: COMPARATOR
Intervention: Standard dosing
Number of subjects: 148
Study 34732500 — intervention group
Group type: EXPERIMENTAL
Intervention: Lengthened dosing interval
Number of subjects: 148
Study 34732666 — intervention group
Group type: EXPERIMENTAL
Intervention: Subluxation supracapsular phacoemulsification
Number of subjects: 292
Study 34732666 — intervention group
Group type: COMPARATOR
Intervention: Divide-and-conquer phacoemulsification
Number of subjects: 292
Study 34732682 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir 300 mg and Cobicistat 150 mg orally once daily during the second trimester
Number of subjects: 11
Study 34732682 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir 300 mg and Cobicistat 150 mg orally once daily during the third trimester
Number of subjects: 11
Study 34732682 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir 300 mg and Cobicistat 150 mg orally once daily postpartum
Number of subjects: 11
Study 34733163 — intervention group
Group type: EXPERIMENTAL
Intervention: BuqiTongluo Granule
Number of subjects: 0
Study 34733947 — intervention group
Group type: EXPERIMENTAL
Intervention: CTCA prior to angiography
Number of subjects: 688
Study 34733947 — intervention group
Group type: COMPARATOR
Intervention: ICA alone
Number of subjects: 688